Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
263 results about "C-Met" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
C-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.
c-Met kinase binding proteins
InactiveUS20060008844A1Stimulate and inhibit activityCompound screeningPeptide librariesKinase bindingC-Met
Owner:AMGEN MOUNTAIN VIEW
Methods and compositions for inhibiting c-met dimerization and activation
InactiveUS20050233960A1High activityHigh expressionSenses disorderPeptide/protein ingredientsC-MetBiochemistry
The invention provides methods and compositions for modulating the HGF / c-met signaling pathway, in particular by regulating c-met dimerization and / or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization.
Owner:GENENTECH INC
Humanized Anti-CMET Antagonists
InactiveUS20070092520A1Effectively treating said mammalEffectively preventingAnimal cellsHybrid immunoglobulinsMedicineC-Met
Owner:GENENTECH INC
Antibody specifically binding to c-met and use thereof
Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.
Owner:SAMSUNG ELECTRONICS CO LTD
c-MET kinase binding proteins
InactiveUS20060177831A1Stimulate and inhibit activityCompound screeningApoptosis detectionKinase bindingC-Met
Owner:AMGEN MOUNTAIN VIEW
Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
ActiveUS20140079774A1Promoting death of cancer cellEfficient packagingBiocideSpecial deliveryLipid formationBinding peptide
The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and / or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis / cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC +1
Bispecific Anti ErbB1 / Anti c Met Antibodies
InactiveUS20100254989A1Highly valuable propertyDecreased internalizationHybrid immunoglobulinsSugar derivativesC-MetErbB
The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Owner:ROCHE GLYCART AG
Humanized anti-cmet antagonists
ActiveUS20060134104A1Effectively treating said mammalEffectively preventingHybrid immunoglobulinsAntibody mimetics/scaffoldsMedicineC-Met
Owner:GENENTECH INC
Bispecific Anti ErbB3 / Anti cMet Antibodies
InactiveUS20100256339A1Highly valuable propertyDecreased internalizationHybrid immunoglobulinsSugar derivativesC-MetBispecific antibody
The present invention relates to bispecific antibodies against human ErbB-3 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Owner:ROCHE GLYCART AG
C-Met Modulators and Methods of Use
The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds and compositions.
Owner:EXELIXIS INC
Methods and compositions for modulating hyperstabilized c-met
ActiveUS20060270594A1High activityHigh expressionPeptide/protein ingredientsGenetic material ingredientsC-MetMET Receptor Tyrosine Kinase
The invention provides methods and compositions for modulating the HGF / c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.
Owner:GENENTECH INC
Triazolotriazine compounds and uses thereof
The present invention relates to compounds of the Formula (I), and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
Owner:SUGEN INC
Antibody specifically binding to c-Met and methods of use
Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.
Owner:SAMSUNG ELECTRONICS CO LTD
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
![Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same](https://images-eureka.patsnap.com/patent_img/6eb9e311-7c53-4109-b28d-edce4eabd58b/US08420645-20130416-D00001.png "Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same")
![Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same](https://images-eureka.patsnap.com/patent_img/6eb9e311-7c53-4109-b28d-edce4eabd58b/US08420645-20130416-D00002.png "Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same")
![Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same](https://images-eureka.patsnap.com/patent_img/6eb9e311-7c53-4109-b28d-edce4eabd58b/US08420645-20130416-D00003.png "Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same")
Owner:INCYTE HLDG CORP
Antibodies to c-Met
ActiveUS7498420B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsSingle-Chain AntibodiesHeavy chain
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and / or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Owner:AMGEN FREMONT INC +1
Methods and compositions for modulating HGF/Met
InactiveUS20060035278A9Effectively treating or preventing said cell proliferative disorderHigh activityCompound screeningApoptosis detectionC-MetMET Receptor Tyrosine Kinase
Owner:GENENTECH INC
Combination therapy with c-met and her antagonists
InactiveUS20090226455A1Significant anti-tumor activityFacilitates heterodimerizationAntibody ingredientsImmunoglobulinsC-MetFactor ii
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
Owner:GENENTECH INC
Antibodies to c-Met
ActiveUS20100040629A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsSingle-Chain AntibodiesHeavy chain
Owner:AMGEN FREMONT INC +1
c-Met modulators and methods of use
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and / or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Owner:EXELIXIS INC
2-aminopyridine kinase inhibitors
InactiveUS20090197862A1Useful in treatmentReduce usageBiocideOrganic chemistryKinase inhibitionEnzyme inhibitor
2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and / or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.
Owner:OSI PHARMA LLC
Methods for treating cancers associated with constitutive EGFR signaling
InactiveUS20090042906A1Promote growthReduced viabilityOrganic active ingredientsDisease diagnosisC-MetMET Receptor Tyrosine Kinase
Owner:MASSACHUSETTS INST OF TECH
Detection of cancer cells in body fluids
A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and β-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
Owner:JOHN WAYNE CANCER INST
Biological materials related to c-Met
The present invention relates to biological materials related to c-Met possibly in combination with VEGF and / or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
Owner:SANOFI SA
Bispecific Anti ErbB2 / Anti cMet Antibodies
InactiveUS20100254988A1Highly valuable propertyDecreased internalizationHybrid immunoglobulinsSugar derivativesC-MetErbB
The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Owner:ROCHE GLYCART AG
Methods and compositions for modulating hyperstabilized c-met
ActiveUS7615529B2High activityEliminate side effectsBiocidePeptide/protein ingredientsC-MetMET Receptor Tyrosine Kinase
The invention provides methods and compositions for modulating the HGF / c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.
Owner:GENENTECH INC
Positive electrode material of multi-element layered lithium ion battery and preparation method thereof
The invention discloses a positive electrode material of a multi-element layered lithium ion battery. The chemical general formula of the positive electrode material is LiNiaMbNcO2, and the Li-Ni mixed ranging degree is less than 2%; in the chemical general formula, M is a transition-metal element, N is one or more of Al, Mg, Ti and Zr, and the values of a, or b, or c meet conditions that a+b+c=1, a>0.3, and c<0.03. The preparation method is as follows: preparing a multi-element precursor by virtue of utilizing a coprecipitation method, and then performing lithiation and sintering, thereby obtaining the positive electrode material of a multi-element layered solid solution. Compared with the prior art, the positive electrode material of the multi-element layered lithium ion battery has the advantages that the Li-Ni mixed ranging degree is reduced to less than 2%, so that the positive electrode material has higher coulomb efficiency, better layer structure and stronger bond energy and shorter bond length of metal-oxygen bond and also has better cycle performance and obviously improved thermal stability at a high temperature and a high pressure.
Owner:DONGGUAN AMPEREX TECH
Anti-c-met antibody formulations
InactiveUS20130004484A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsMedicineC-Met
Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same.
Owner:F HOFFMANN LA ROCHE & CO AG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com